Non–clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell‐derived anti–glypican‐3 chimeric antigen receptor‐expressing natural killer/innate lymphoid cells - Ueda, Tatsuki; Kumagai, Ayako; Iriguchi, Shoichi; Yasui, Yutaka; Miyasaka, Tadayo; Nakagoshi, Kengo; Nakane, Kazuki; Saito, Keigo; Takahashi, Mari; Sasaki, Aki; Yoshida, Shinsuke; Takasu, Naoko; et al. (Cancer science, 2020)
Keywords: Antibodies; Antigens; Cancer immunotherapy; Cancer therapies; CD45 antigen; CD7 antigen; Cell differentiation; chimeric antigen receptor; Chimeric antigen receptors; Clinical trials; Cytotoxicity; GPC3; Heparan sulfate proteoglycans; Histocompatibility antigen HLA; ILC; Immunodeficiency; Immunotherapy; Interferon; iPSC; Liver cancer; Lymphatic system; Lymphocytes; Lymphoid cells; Manufacturers; Natural killer cells; Original; Ovarian cancer; Ovaries; Pluripotency; Quality control; Safety; Stem cell transplantation; Stem cells; Tumor cells; Tumorigenicity; Tumors; Japan; GPC3; ILC; chimeric antigen receptor; NK; iPSC; immunotherapy